Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Julphar
Dow
Harvard Business School
Cantor Fitzgerald
Citi
Express Scripts
Johnson and Johnson
Chubb

Generated: June 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 206910

« Back to Dashboard

NDA 206910 describes JADENU, which is a drug marketed by Novartis Pharms Corp and is included in two NDAs. It is available from one supplier. There are two patents protecting this drug and three Paragraph IV challenges. Additional details are available on the JADENU profile page.

The generic ingredient in JADENU is deferasirox. There are twenty drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the deferasirox profile page.
Summary for 206910
Tradename:JADENU
Applicant:Novartis Pharms Corp
Ingredient:deferasirox
Patents:2
Therapeutic Class:Antidotes, Deterrents, and Toxicologic Agents
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 206910
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
JADENU deferasirox TABLET;ORAL 206910 NDA Novartis Pharmaceuticals Corporation 0078-0654 N 0078-0654-15
JADENU deferasirox TABLET;ORAL 206910 NDA Novartis Pharmaceuticals Corporation 0078-0655 N 0078-0655-15

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength90MG
Approval Date:Mar 30, 2015TE:RLD:Yes
Regulatory Exclusivity Expiration:Jan 23, 2020
Regulatory Exclusivity Use:TREATMENT OF CHRONIC IRON OVERLOAD IN PATIENTS 10 YRS. & OLDER WITH NON-TRANSFUSION DEPENDENT THALASSEMIA (NTDT) SYNDROMES AND WITH A LIVER IRON CONCENTRATION OF AT LEAST 5 MG OF IRON PER GRAM OF LIVER DRY WEIGHT & SERUM FERRITIN GREATER THAN 300 MCG/L.
Patent:➤ Sign UpPatent Expiration:Apr 5, 2019Product Flag?YSubstance Flag?YDelist Request?
Patent:➤ Sign UpPatent Expiration:Nov 21, 2034Product Flag?YSubstance Flag?YDelist Request?

Expired US Patents for NDA 206910

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis Pharms Corp JADENU deferasirox TABLET;ORAL 206910-002 Mar 30, 2015 ➤ Sign Up ➤ Sign Up
Novartis Pharms Corp JADENU deferasirox TABLET;ORAL 206910-003 Mar 30, 2015 ➤ Sign Up ➤ Sign Up
Novartis Pharms Corp JADENU deferasirox TABLET;ORAL 206910-001 Mar 30, 2015 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
UBS
Argus Health
Accenture
Deloitte
Daiichi Sankyo
Johnson and Johnson
Cantor Fitzgerald
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.